Reyes Jiménez-Bárcenas, Gloria García-Donas-Gabaldón, Rosa María Campos-Álvarez, María Carmen Fernández-Sánchez de Mora, Josefa Luis-Navarro, Juan Francisco Domínguez-Rodríguez, María Del Mar Nieto-Hernández, Irene Sánchez-Bazán, Maria Yera-Cobo, Rocio Cardesa-Cabrera, Francisco José Jiménez-Gonzalo, María Antonia Ruiz-Cobo, Isabel Caparrós-Miranda, Laura Entrena-Ureña, Dolores Fernández Jiménez, Dana Díaz-Canales, Gloria Moreno-Carrasco, Cristina Calderón-Cabrera, Ramiro José Núñez-Vázquez, Begoña Pedrote-Amador, María Eva Mingot-Castellano
Immune thrombocytopenia (ITP) is characterized by low platelet counts (PLTs) and an increased risk of bleeding. Fostamatinib, a spleen tyrosine kinase inhibitor, has been approved as a second-line treatment for ITP. Real-world data on fostamatinib are lacking. This observational, retrospective, multicentre study, conducted in the Andalusia region of Spain, evaluated 44 adult primary ITP patients (47.7% female; median age 58 years; newly diagnosed ITP 6.8%; persistent 13.6%; chronic 79.5%; median four prior treatments) after ≥ 4 weeks of fostamatinib therapy...
April 3, 2024: British Journal of Haematology